查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1609800

2024-2032 年日本细胞治疗市场报告（按细胞类型、治疗类型、治疗领域、最终用户和地区划分）

Japan Cell Therapy Market Report by Cell Type, Therapy Type, Therapeutic Area, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 121 Pages | 商品交期: 5-7个工作天内

价格
简介目录

2023年日本细胞治疗IMARC Group规模达3.176亿美元。推动市场的一些因素包括患者知识的增加、政府支持的增加以及保险覆盖范围的扩大。

细胞疗法 (CT) 涉及人体细胞的转移，以解决组织和细胞的损伤，为各种医疗状况提供补救措施。这种综合方法包括各种类型的细胞，例如造血干细胞 (HSC)、骨骼肌和间质干细胞、淋巴细胞、树突状细胞和胰岛细胞。其应用不仅限于增强癌症治疗的免疫系统，还包括治疗自体免疫疾病和传染病、泌尿问题、关节软骨损伤、脊髓损伤、免疫系统受损和神经系统疾病。它在再生药物的生产中发挥着至关重要的作用，促进创新疗法的创建和实施，旨在修復组织和器官以及恢復受衰老、疾病或损伤影响的功能。

日本细胞治疗市场趋势：

日本细胞治疗市场主要受到生物技术快速发展的刺激。这一发展得到了研发工作显着增加的补充，这些工作在市场的成长中发挥着重要作用。此外，来自政府和私人投资者的资金涌入进一步推动了细胞疗法的研究和商业化。此外，临床试验活动的扩大有助于验证细胞疗法的有效性和安全性，从而加速市场扩张。慢性病和退化性疾病盛行率的不断上升正在创造对先进治疗方案的需求，从而推动市场向前发展。随着人口老化，针对年龄相关疾病的再生疗法的需求越来越大，从而巩固了市场。此外，针对个别患者的个人化细胞疗法的日益普及正在促进市场的成长。监管机构也为细胞疗法的批准提供了更明确的途径，从而培育了积极的市场前景。竞争格局正在推动细胞治疗产品的创新和多样化，而罕见疾病发病率的不断上升进一步推动了市场的上升轨迹。

日本细胞治疗市场细分：

细胞类型见解：

  • 干细胞
  • 骨髓
  • 血
  • 脐带来源
  • 脂肪干细胞
  • 其他的
  • 非干细胞

治疗类型见解：

  • 自体
  • 同种异体

治疗领域见解：

  • 恶性肿瘤
  • 肌肉骨骼疾病
  • 自体免疫疾病
  • 皮肤科
  • 其他的

最终使用者见解：

  • 医院和诊所
  • 学术及研究机构

竞争格局：

市场研究报告也对竞争格局进行了全面分析。报告涵盖了市场结构、关键参与者定位、最佳制胜策略、竞争仪表板和公司评估象限等竞争分析。此外，也提供了所有主要公司的详细资料。

本报告回答的关键问题：

  • 日本细胞治疗市场迄今表现如何，未来几年又将如何表现？
  • COVID-19 对日本细胞治疗市场有何影响？
  • 日本细胞治疗市场以细胞类型划分是怎样的？
  • 日本细胞治疗市场按治疗类型划分是怎样的？
  • 日本细胞治疗市场依治疗领域划分是怎样的？
  • 日本细胞治疗市场的最终用户细分情况如何？
  • 日本细胞治疗市场价值链的各个阶段是什么？
  • 日本细胞疗法的关键驱动因素和挑战是什么？
  • 日本细胞治疗市场的结构如何？
  • 日本细胞治疗市场的竞争程度如何？

本报告回答的关键问题：

  • 日本细胞治疗市场迄今表现如何，未来几年又将如何表现？
  • COVID-19 对日本细胞治疗市场有何影响？
  • 日本细胞治疗市场以细胞类型划分是怎样的？
  • 日本细胞治疗市场按治疗类型划分是怎样的？
  • 日本细胞治疗市场依治疗领域划分是怎样的？
  • 日本细胞治疗市场的最终用户细分情况如何？
  • 日本细胞治疗市场价值链的各个阶段是什么？
  • 日本细胞疗法的关键驱动因素和挑战是什么？
  • 日本细胞治疗市场的结构如何？
  • 日本细胞治疗市场的竞争程度如何？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：日本细胞治疗市场 - 简介

  • 概述
  • 市场动态
  • 产业动态
  • 竞争情报

第 5 章：日本细胞治疗市场格局

  • 历史与当前市场趋势（2018-2023）
  • 市场预测（2024-2032）

第 6 章：日本细胞治疗市场 - 细分：按细胞类型

  • 干细胞
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场区隔
      • 骨髓
      • 血
      • 脐带来源
      • 脂肪干细胞
      • 其他的
    • 市场预测（2024-2032）
  • 非干细胞
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）

第 7 章：日本细胞治疗市场 - 细分：依治疗类型

  • 自体
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 同种异体
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）

第 8 章：日本细胞治疗市场 - 细分：依治疗领域

  • 恶性肿瘤
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 肌肉骨骼疾病
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 自体免疫疾病
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 皮肤科
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 其他的
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）

第 9 章：日本细胞治疗市场 - 细分：按最终用户划分

  • 医院和诊所
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）
  • 学术及研究机构
    • 概述
    • 历史与当前市场趋势（2018-2023）
    • 市场预测（2024-2032）

第 10 章：日本细胞治疗市场 - 竞争格局

  • 概述
  • 市场结构
  • 市场参与者定位
  • 最佳制胜策略
  • 竞争仪表板
  • 公司评估象限

第 11 章：关键参与者简介

  • Company A
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company B
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company C
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company D
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events
  • Company E
    • Business Overview
    • Product Portfolio
    • Business Strategies
    • SWOT Analysis
    • Major News and Events

第 12 章：日本细胞治疗市场 - 产业分析

  • 驱动因素、限制因素和机会
    • 概述
    • 司机
    • 限制
    • 机会
  • 波特五力分析
    • 概述
    • 买家的议价能力
    • 供应商的议价能力
    • 竞争程度
    • 新进入者的威胁
    • 替代品的威胁
  • 价值链分析

第 13 章：附录

简介目录
Product Code: SR112024A19882

Japan cell therapy market size reached US$ 317.6 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,782.8 Million by 2032, exhibiting a growth rate (CAGR) of 18.70% during 2024-2032. Some of the factors driving the market include the increasing knowledge among patients, the rising backing from the government, and the widening scope of insurance coverage.

Cell therapy (CT) involves the transfer of human cells to address damage to tissues and cells, offering remedies for various medical conditions. This comprehensive approach includes various types of cells such as hematopoietic stem cells (HSC), skeletal muscle and mesenchymal stem cells, lymphocytes, dendritic cells, and pancreatic islet cells. Its applications go beyond strengthening the immune system for cancer treatment and also encompass the treatment of autoimmune and infectious diseases, urinary issues, joint cartilage damage, spinal cord injuries, compromised immune systems, and neurological disorders. It plays a crucial role in the production of regenerative medicines, facilitating the creation and implementation of innovative treatments aimed at the restoration of tissues and organs and the recovery of functions affected by aging, diseases, or injuries.

Japan Cell Therapy Market Trends:

The Japan cell therapy market is primarily stimulated by the rapid progressions in biotechnology. This development is complemented by a notable increase in research and development endeavors, which are playing a significant role in the market's growth. Additionally, the influx of funding from both governmental sources and private investors is further fueling the research and commercialization of cell therapy. Furthermore, the expansion of clinical trial activities serves to authenticate the effectiveness and safety of cell therapies, thereby accelerating market expansion. The escalating prevalence of chronic and degenerative diseases is creating a demand for advanced treatment options, consequently propelling the market forward. With an aging population, there is a growing necessity for regenerative therapies tailored to age-related conditions, thus fortifying the market. Moreover, the increasing popularity of personalized cell therapies tailored to individual patients is fostering the growth of the market. Regulatory agencies are also providing clearer pathways for the approval of cell therapy, fostering a positive outlook for the market. The competitive landscape is driving innovation and diversification of cell therapy products, while the escalating incidence of rare diseases is further contributing to the market's upward trajectory.

Japan Cell Therapy Market Segmentation:

Cell Type Insights:

  • Stem Cell
  • Bone Marrow
  • Blood
  • Umbilical Cord-Derived
  • Adipose-Derived Stem Cell
  • Others
  • Non-stem Cell

Therapy Type Insights:

  • Autologous
  • Allogeneic

Therapeutic Area Insights:

  • Malignancies
  • Musculoskeletal Disorders
  • Autoimmune Disorders
  • Dermatology
  • Others

End User Insights:

  • Hospitals and Clinics
  • Academic and Research Institutes

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

  • How has the Japan cell therapy market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Japan cell therapy market?
  • What is the breakup of the Japan cell therapy market on the basis of cell type?
  • What is the breakup of the Japan cell therapy market on the basis of therapy type?
  • What is the breakup of the Japan cell therapy market on the basis of therapeutic area?
  • What is the breakup of the Japan cell therapy market on the basis of end user?
  • What are the various stages in the value chain of the Japan cell therapy market?
  • What are the key driving factors and challenges in the Japan cell therapy?
  • What is the structure of the Japan cell therapy market and who are the key players?
  • What is the degree of competition in the Japan cell therapy market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Cell Therapy Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Cell Therapy Market Landscape

  • 5.1 Historical and Current Market Trends (2018-2023)
  • 5.2 Market Forecast (2024-2032)

6 Japan Cell Therapy Market - Breakup by Cell Type

  • 6.1 Stem Cell
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2018-2023)
    • 6.1.3 Market Segmentation
      • 6.1.3.1 Bone Marrow
      • 6.1.3.2 Blood
      • 6.1.3.3 Umbilical Cord-Derived
      • 6.1.3.4 Adipose-Derived Stem Cell
      • 6.1.3.5 Others
    • 6.1.4 Market Forecast (2024-2032)
  • 6.2 Non-stem Cell
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2018-2023)
    • 6.2.3 Market Forecast (2024-2032)

7 Japan Cell Therapy Market - Breakup by Therapy Type

  • 7.1 Autologous
    • 7.1.1 Overview
    • 7.1.2 Historical and Current Market Trends (2018-2023)
    • 7.1.3 Market Forecast (2024-2032)
  • 7.2 Allogeneic
    • 7.2.1 Overview
    • 7.2.2 Historical and Current Market Trends (2018-2023)
    • 7.2.3 Market Forecast (2024-2032)

8 Japan Cell Therapy Market - Breakup by Therapeutic Area

  • 8.1 Malignancies
    • 8.1.1 Overview
    • 8.1.2 Historical and Current Market Trends (2018-2023)
    • 8.1.3 Market Forecast (2024-2032)
  • 8.2 Musculoskeletal Disorders
    • 8.2.1 Overview
    • 8.2.2 Historical and Current Market Trends (2018-2023)
    • 8.2.3 Market Forecast (2024-2032)
  • 8.3 Autoimmune Disorders
    • 8.3.1 Overview
    • 8.3.2 Historical and Current Market Trends (2018-2023)
    • 8.3.3 Market Forecast (2024-2032)
  • 8.4 Dermatology
    • 8.4.1 Overview
    • 8.4.2 Historical and Current Market Trends (2018-2023)
    • 8.4.3 Market Forecast (2024-2032)
  • 8.5 Others
    • 8.5.1 Historical and Current Market Trends (2018-2023)
    • 8.5.2 Market Forecast (2024-2032)

9 Japan Cell Therapy Market - Breakup by End User

  • 9.1 Hospitals and Clinics
    • 9.1.1 Overview
    • 9.1.2 Historical and Current Market Trends (2018-2023)
    • 9.1.3 Market Forecast (2024-2032)
  • 9.2 Academic and Research Institutes
    • 9.2.1 Overview
    • 9.2.2 Historical and Current Market Trends (2018-2023)
    • 9.2.3 Market Forecast (2024-2032)

10 Japan Cell Therapy Market - Competitive Landscape

  • 10.1 Overview
  • 10.2 Market Structure
  • 10.3 Market Player Positioning
  • 10.4 Top Winning Strategies
  • 10.5 Competitive Dashboard
  • 10.6 Company Evaluation Quadrant

11 Profiles of Key Players

  • 11.1 Company A
    • 11.1.1 Business Overview
    • 11.1.2 Product Portfolio
    • 11.1.3 Business Strategies
    • 11.1.4 SWOT Analysis
    • 11.1.5 Major News and Events
  • 11.2 Company B
    • 11.2.1 Business Overview
    • 11.2.2 Product Portfolio
    • 11.2.3 Business Strategies
    • 11.2.4 SWOT Analysis
    • 11.2.5 Major News and Events
  • 11.3 Company C
    • 11.3.1 Business Overview
    • 11.3.2 Product Portfolio
    • 11.3.3 Business Strategies
    • 11.3.4 SWOT Analysis
    • 11.3.5 Major News and Events
  • 11.4 Company D
    • 11.4.1 Business Overview
    • 11.4.2 Product Portfolio
    • 11.4.3 Business Strategies
    • 11.4.4 SWOT Analysis
    • 11.4.5 Major News and Events
  • 11.5 Company E
    • 11.5.1 Business Overview
    • 11.5.2 Product Portfolio
    • 11.5.3 Business Strategies
    • 11.5.4 SWOT Analysis
    • 11.5.5 Major News and Events

12 Japan Cell Therapy Market - Industry Analysis

  • 12.1 Drivers, Restraints, and Opportunities
    • 12.1.1 Overview
    • 12.1.2 Drivers
    • 12.1.3 Restraints
    • 12.1.4 Opportunities
  • 12.2 Porters Five Forces Analysis
    • 12.2.1 Overview
    • 12.2.2 Bargaining Power of Buyers
    • 12.2.3 Bargaining Power of Suppliers
    • 12.2.4 Degree of Competition
    • 12.2.5 Threat of New Entrants
    • 12.2.6 Threat of Substitutes
  • 12.3 Value Chain Analysis

13 Appendix